Latest News
Ganymed Pharmaceuticals AG Announces
Ganymed to Present Exciting Phase II Clinical Data for IMAB362 in Gastroesophageal Cancer at ASCO 2016 Annual Meeting - May 2016

Our mission

At Ganymed, we aim to revolutionize cancer treatment by developing a new class of therapeutic drugs called Ideal Monoclonal Antibodies (IMABs). IMABs are unique in that they are highly selective for proteins which are present on cancer cells, but do not bind to healthy cells.

Due to this unmatched cancer-cell specificity, IMABs will be high-precision therapeutics that efficiently kill cancer cells without harming normal healthy tissues.

Contact information
Ganymed Pharmaceuticals AG
An der Goldgrube 12
55131 Mainz, GERMANY
+49 (0) 6131 / 1440-100
+49 (0) 6131 / 1440-114